Oligonucleotide Synthesis Market Worth $3.9 Billion by 2025, Growing at a CAGR of 10.4% from 2019- Global Opportunity Analysis and Industry Forecasts by Meticulous Research® London, June 16, 2020 (GLOBE NEWSWIRE) -- The oligonucleotide synthesis market is expected to grow at a CAGR 10.4% from 2019 to 2025 to reach $3.9 billion by 2025. Oligonucleotide-based therapy and...

NapaJen Pharma and Astellas Pharma Establish Research Collaboration for Discovery and Development of Novel Oligonucleotides BURLINGAME, Calif. and TOKYO, March 18, 2019 (GLOBE NEWSWIRE) -- NapaJen Pharma, Inc., a biotherapeutics company leveraging its proprietary oligonucleotide delivery technology to develop novel...

NapaJen Pharma Announces First Patient Dosed in Phase 1 First-in-Human Clinical Trial of Novel RNA Interference (RNAi) Therapeutic NJA-730 is an Anti-CD-40 Small Interfering RNA (siRNA) Combined with Beta-Glucan Delivery Vehicle with Potential to Treat Acute Graft-versus-Host Disease Program Leverages NapaJen’s Immune...

MDRNA, Inc. Appoints James M. Karis to Its Board of Directors BOTHELL, WA--(Marketwire - August 11, 2009) - MDRNA, Inc. (NASDAQ: MRNA) announced today that James M. Karis has been appointed to the Company's Board of Directors. His appointment brings the number...